Skip to main content

p63/TP73L Antibody (TP40/3980R) [PE]

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-08775PE

Recombinant Monoclonal Antibody
Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP3-08775PE

Key Product Details

Species Reactivity

Human

Applications

Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin

Label

PE (Excitation = 488 nm, Emission = 575 nm)

Antibody Source

Recombinant Monoclonal Rabbit IgG Clone # TP40/3980R

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

A synthetic peptide from the N-terminal of human p63/TP73Lprotein (Exact sequence is proprietary) (Uniprot: Q9H3D4 )

Localization

Nuclear

Specificity

p63 consists of two major isoforms-TAp63 and delta-Np63. These isoforms differ in the structure of the N-terminal domains. The TAp63 isoform (identified by anti-p63 antibody) contains a transactivation-competent TA domain with homology to p53, which regulates the expression of the growth-inhibitory genes. In contrast, DNp63 isoform (identified by anti-p40 antibody) contains an alternative transcriptionally-inactive delta-N domain, which antagonizes the activity of TAp63 and p53. P40/3980R recognizes exclusively delta-Np63 but not TAp63. p40 is a squamous cell carcinoma specific antibody. It reacts with the vast majority of cases of squamous cell carcinomas of various origins, but not with adenocarcinomas. It is particularly useful in differentiating lung squamous cell carcinoma from lung poorly differentiated adenocarcinoma. p40 antibody can also be used as an alternative basal cell/myoepithelial cell marker, which has similar sensitivity and specificity as that of p63 antibody. Therefore, p40 antibody may also be used as an alternative immunohistochemical marker for determining prostate adenocarcinoma vs. benign prostate glands and for determining breast intraductal carcinoma vs. invasive breast ductal carcinoma.

Marker

Squamous, Basal & Myoepithelial Cell Marker

Clonality

Monoclonal

Host

Rabbit

Isotype

IgG

Applications for p63/TP73L Antibody (TP40/3980R) [PE]

Application
Recommended Usage

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Immunocytochemistry/ Immunofluorescence

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry-Paraffin

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

PBS

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: p63/TP73L

The p63 gene, a homologue of the tumor suppressor p53, is highly expressed in the basal or progenitor layers of many epithelial tissues. P63 shows remarkable structural similarity to p53 and to the related p73 gene. Unlike p53, the p63 gene encodes multiple isotypes with remarkably divergent abilities to transactivate p53 reporter genes and induce apoptosis.

Long Name

Tumor Protein 63

Alternate Names

EEC3, KET, OFC8, p40, p51, p73L, SHFM4, TP63, TP73L

Gene Symbol

TP63

Additional p63/TP73L Products

Product Documents for p63/TP73L Antibody (TP40/3980R) [PE]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for p63/TP73L Antibody (TP40/3980R) [PE]

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...